Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

With the demonstration of improved survival of some acute myeloid leukemia (AML) patients with the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO), CD33 has been validated as a target for antigen-specific immunotherapy. Since previous studies identified a CD33 splice variant missing exon 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Laszlo, George S., Harrington, Kimberly H., Gudgeon, Chelsea J., Beddoe, Mary E., Fitzgibbon, Matthew P., Ries, Rhonda E., Lamba, Jatinder K., McIntosh, Martin W., Meshinchi, Soheil, Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190023/
https://www.ncbi.nlm.nih.gov/pubmed/27248327
http://dx.doi.org/10.18632/oncotarget.9674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190023/
https://www.ncbi.nlm.nih.gov/pubmed/27248327
http://dx.doi.org/10.18632/oncotarget.9674

Ejemplares similares